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Abstract Translational researchers and clinicians recom-
mend the use of large animal models in preclinical stroke
research. This represents an important part of a strategy
aiming to prevent past translational failures in future
therapeutic developments. Thirty-five Merino rams were
subjected to sham surgery (n=3), one-branch middle
cerebral artery occlusion (MCAO, n=8) or total MCAO
(n=24). Twelve animals from the latter group received
intravenous administration of 4×106 autologous mononu-
clear bone marrow cells (BM MNC) per kilogram 24 h after
total MCAO. Animals were sacrificed at day 49 post
MCAO. Histological investigations were performed to
reveal (1) the impact of different MCAO modalities on a
cellular level and (2) the influence of BM MNC therapy
following stroke. Clear differences between one-branch and
total MCAO were observed histologically with results
being comparable to those seen in human patients. BM
MNC treatment reduced final lesion extension, lymphocytic
infiltration and axonal degeneration after MCAO. The
sheep model may represent a feasible tool for translational
stroke research as pathohistological findings mimic the
situation in humans. Histological evidence was found for
beneficial impact of autologous BM MNC therapy. Further
studies are needed to assess the neurofunctional impact of
the approach in the gyrencephalic brain.
Keywords Stroke . Brain ischaemia . Large animal model .
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Introduction
Ischaemic stroke represents a major cause of death and is
the most prominent reason for permanent disability in
adulthood [1]. The only effective and FDA-approved
therapy for the disease is intravenous thrombolysis [2].
The narrow time window of 4.5 h following onset of
ischaemia [3] and numerous contraindications [4] still
exclude the majority of patients (>95%) from treatment
[5]. Thus, novel therapeutic options for ischaemic stroke
are strongly demanded. Cell therapies, in particular the use
of bone-marrow-derived (stem) cell populations, are among
the most promising approaches [6]. Efficacy and safety of
bone marrow stromal cells (BMSC) and mononuclear cells
(BM MNC) has been shown in preclinical experiments.
Neuroprotective, immunomodulatory and plasticity-
enhancing properties of BMSC [7-9] and BM MNC [10-
12], rather than direct cell replacement by differentiation
and integration, were reported as mediators of beneficial
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effects. Excellent data is available on the therapeutic time
window for BM MNC treatment [13, 14], while autologous
application of those cells is considered relatively uncritical
in human patients. Moreover, first in-man studies revealed
safety of intravenous and intra-arterial [15] application of
autologous BM MNC following stroke in humans, encour-
aging further clinical research on this treatment paradigm.
However, numerous therapeutic strategies for focal
cerebral ischaemia had been developed during the last
decades, predominantly focussing on post-stroke neuro-
protection. Despite promising preclinical results and suc-
cessful safety assessments in patients [16] in many cases,
not a single approach was proven to be effective in clinical
trials [17]. The reasons for this disappointing situation are
considered numerous. There is a common understanding
that suboptimal design of preclinical experiments and
improper animal models may at least partially account for
this dilemma. Consequently, more thorough and rigorous
standards for preclinical research were demanded by
translational stroke researchers and clinicians. The “Stem
Cell Therapy as an Emerging Paradigm for Stroke”
(STEPS) international expert consortium published recom-
mendations for cell-based stroke research [18, 19] in order
to enhance the predictive value of animal experiments and
thereby to reduce the risk of failure of an experimental
treatment approach in the clinic. An important recommen-
dation is to test a therapeutic candidate in large animal
models of stroke to estimate its influence in the gyrence-
phalic brain [19].
Numerous large animal models of middle cerebral artery
occlusion (MCAO) including the use of canine [20], feline
[21] and non-human primates [22] species are available.
Albeit being of utmost importance for stroke research,
invasive experimental and surgical procedures (e.g. enucle-
ation to assess the MCA) in these models may lead to high
post-stroke mortality [23], thus limiting applicability for
long-term safety and efficacy assessments. An alternative
ovine MCAO model was recently introduced by our group
[24], which allows control of lesion size as well as
neurofunctional impact, implementation of modern imaging
techniques and long-term survival of experimental subjects.
The pathological findings in this model are basically
comparable to those obtained in human stroke victims.
However, more detailed knowledge about the histopatho-
logical consequences of MCAO is needed to enhance the
use of the sheep model in translational stroke research. This
holds particularly true for cell therapy research, as distinct
modulations on the cellular level are expected to be the
major mode of actions in cell therapies for stroke [6]. Here,
we describe (1) the pathohistological impact of permanent
partial and total cortical MCAO and (2) provide first data




All experiments were approved by the commission for
animal welfare at the regional board of Leipzig (animal
license numbers 05/04 and 16/07). A total number of 35
hornless Merino rams with an average weight of 60.3 (45–
100) kg and average age of 10.2 (8–18) months were
enrolled in this study. Animals were housed in groups of up
to six rams in capacious stable boxes (minimum 2.5 m2 per
animal) with ad libitum access to food and water at the
Faculty for Veterinary Medicine, University of Leipzig.
Prior to surgery and starting 5 days thereafter, rams were
allowed to graze on areas next to the stable for at least 5 h
per day. Food (but not water) restriction was applied 24 h
before surgery.
Study Design and Induction of Focal Cerebral Ischaemia
Animals were assigned to the following experimental
groups: sham surgery (n=3), one-branch (partial) MCAO
(n=8), total MCAO without (n=12) or with (n=12)
application of autologous BM MNC 24 h after stroke.
MCAO in the left hemisphere was induced as described
elsewhere [24]. Briefly, animals were initially anaesthetised
by intravenous injection of 4.0 mg/kg ketamine (Medistar
Ltd., Holzwickede, Germany), 0.1 mg/kg xylazine (Ceva
Sante Animal Ltd., La Ballastiére, France) and 0.2 mg/kg
midazolame (Braun Melsungen, Melsungen, Germany).
Intramuscular buprenorphine (0.01 mg/kg, Temgesic®,
RB Pharmaceuticals, Berkshire, UK) was used for peri-
and postsurgical pain management. After loss of conscious-
ness, subjects were immediately intubated and quickly
transferred to the operating room. Anaesthesia was main-
tained by respiration with 2% isofluran (WDTeG, Garbsen,
Germany) in 30% oxygen. Continuous monitoring of
electrocardiogram, blood pressure, blood oxygenation,
expiratory carbon dioxide content and body temperature
(rectal) was performed. After local antiseptic treatment, an
elliptic skin flap was removed from the shaved skin
between the eye and the ear, followed by electrocoagulation
of the temporal artery and vein. After incision at the
temporal line, the temporal muscle was transiently elevated
from the parietal skull bone. A small trepanation of
approximately 1×1 cm was performed behind the orbital
rim for direct access to the MCA. Following incision of the
dura, the artery was touched by bipolar forceps (sham
group). Alternatively, either the caudal parietal MCA
branch (partial MCAO) or the entire cortical vessel
(regularly also supplying subcortical areas) was occluded
(total MCAO). The temporal muscle was refixed to the
temporal line using 2–0 resorbable filaments (Vicryl 2–0,
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Ethicon, Norderstedt, Germany). After suturing of the skin
wound using identical surgical filaments and final superfi-
cial antiseptic/antibiotic treatment, animals were taken back
to the stable and were allowed to recover. Intravenous
antibiotic and analgetic treatment by 5 mg/kg enrofloxacin
and 2.2 mg/kg flunixin, respectively, was performed for
7 days post-surgery. Daily inspections and health checks
were performed by skilled veterinarians until the end of the
trial. All animal survived the procedure and quickly
recovered from surgery.
Isolation of BM MNC, Baseline Infarct Volumetry
and Autologous Cell Transplantation
Twenty hours after MCAO, animals were again weighted
and re-anaesthetized by intravenous injection as described
above. Subjects were placed in prone position and the areas
around both iliac crests were shaved. Following superficial
antiseptic treatment, bone marrow specimens (approximate-
ly 60 to 80 mL) were collected in 20,000 IU of heparin in
two sterile 50-mL perfusor syringes by repeated puncture of
the iliac crests on both sides. Bone marrow punctuate was
transferred immediately to a clean bench for further
processing. The volume of BM aspirates was doubled by
adding sterile phosphate-buffered saline (PBS, Biochrom
AG, Berlin, Germany). MNC were obtained by density
gradient centrifugation using a 1:1 (v/v) mixture of LSM
1077® (1.077 g/mL, PAA Laboratories GmbH, Cölbe,
Germany) and Pancoll® (1.089 g/mL, PAN-Biotech GmbH,
Aidenbach, Germany) at 1,000×g for 25 min. After two
washing steps in PBS, the number of vital BM MNC was
assessed using the Trypan Blue® (Sigma-Aldrich GmbH,
Hamburg, Germany) method and a Neubauer counting
chamber (Carl-Roth GmbH, Karlsruhe, Germany). During
the time of BM MNC separation, animals were subjected to
1.5 T turbo spin echo (T2 TSE) magnetic resonance
imaging (MRI) to reveal initial lesion size in all groups.
Please refer to [24] for methodological details. A weight-
adapted transplantation paradigm was applied. Immediately
before transplantation, 4×106 autologous BM MNC per
kilogram bodyweight were stored in 20 mL of PBS and
injected intravenously 24 h following MCAO (directly after
MRI), within 15 min after assessment of cell viability.
Termination of Study and Histological Investigations
Seven weeks after MCAO, animals were euthanized by
intravenous injection of 15 mL pentobarbital (Eutha77®,
Essex Pharma Ltd, Munich, Germany) after induction of
deep anaesthesia. Heart action was monitored continuously.
Death was confirmed by two independent veterinarians
after heart beats and respiratory movements were clearly
absent for at least 2 min. Animals were then rapidly
decapitated at the atlanto-occipital junction. Both carotid
arteries were exposed and blunt 2 mm perfusion cannulas
were inserted into each vessel. The heads were perfused
with 1.5 L PBS, followed by 15 L 4% paraformaldehyde
(PFA). The skull cap was carefully removed with an
oscillating saw (HEBUmedical AG, Tuttlingen, Germany)
and the dura was opened. Afterwards, the heads were stored
for at least 24 h in 4% PFA for immersion fixation before
the brain was removed for further processing.
Gross Pathology and Volumetry
After removal, PFA-fixed brains were weighted and largest
vertical and horizontal (including cerebellum) circumfer-
ences were measured. Brains were further photographed
from each side using a Nikon DX 100 digital camera.
Thereafter, 4 mm coronal brain slices were cut (Fig. 1a) and
photographed from the rostral and occipital direction. From
digital photographs, the surface area of the infarct, the area
of the ipsilateral (ischaemic) and the contralateral hemi-
sphere (without ventricles), as well as the areas of the
corresponding lateral ventricles were calculated for each
slice (Ar=area from rostral view, Ao=area from occipital
view, in square centimetres, Fig. 1b) using the Image J 1.39
open source software [25]. The total volumes (Vtotal) of
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and n is the number of partial volumes (slices) for the
individual brain (ranging from 17 to 19). The ventricular
expansion (vE) in the ischaemic hemisphere at day 49 post






whereas V leV½ total represents the total volume of the left
(ischaemic side) lateral ventricle and V riV½ total indicates the
total volume of the right lateral ventricle, respectively. All
investigations were performed by a researcher not aware of
the group allocation.
Preparation of Brain Slices for Histological Investigations
For histological studies, two consecutive 4-mm slices were
analysed from three different areas of the infarct: two slices
each from the rostral and occipital border of the infarction,
Transl. Stroke Res. (2011) 2:279–293 281
and two slices from the level of MCAO (central part of the
lesion). All slices were analysed in four different regions:
the ipsilateral (left) leptomeninx in the area of the MCA,
the central lesion zone, the bordering (200 μm wide)
reactive zone as well as the unaffected remote zone
(Fig. 1c) in accordance to [26]. In both, the reactive and
the remote zone, grey (cortical) and white (medullary)
matters (Fig. 1c) were distinguished for separate analysis.
Where appropriate, a comparison to corresponding areas in
the contralateral (right) hemisphere (Fig. 1c) was also
performed. Brain slices were embedded in paraffin (Hyper-
Center®, Shandon, Germany). From each zone, 4-μm thick
slices were cut using a microtome (Medim GmbH, Gießen,
Germany) and mounted on SuperFrost® slides (Carl-Roth
GmbH, Karlsruhe, Germany) for staining and microscopic
analysis.
Histological Stainings
All slices were alternately stained with hematoxylin and
eosin (HE, for morphological assessments) or more
specialized (Picrosirius red and Kossa) stainings.
HE staining [27] was employed to assess proliferation of
connective tissue, perivascular cellular infiltrations, blood
vessel density and signs of hypoxic–ischaemic neuronal
alterations. The latter comprise spheroids (indicating axonal
degeneration) and cytolytic neuronal alterations (e.g.
“ghost” neurons) [26]. Previous histological studies [24]
revealed that ovine microglia can be stained using anti-
CD11b and biotinylated potato (Solanum tuberosum) lectin
(STL), which, however, may also label neutrophils (CD11b)
and capillary walls (STL). Therefore, HE staining was also
used to identify recruited microglial cells by their rod-
shaped nucleus [26].
Kossa (Ko) staining [27] was applied for visualisation of
focal or diffuse mineral deposits (“calcification”, black
staining). Picrosirius red (PsR) staining [28, 29] was used to
describe morphology and also proliferation of connective
tissue resulting in collagen fibres appearing red, blue-
stained mucopolysaccharids appearing, and brown nuclei.
Polarized light (see below) was further used to detect
(yellow) collagen type I and (green) type III fibres [28].
Microscopy and Histological Evaluation of Brain Specimen
Histological analysis was performed by a researcher trained
in veterinary pathology. In case of doubts, senior veterinary
and human pathologists were consulted. All investigators
were unaware of group allocation of investigated specimen.
An Olympus BH2 microscope (Olympus GmbH, Ham-
burg, Germany) equipped with ×4, ×10, ×20 and ×40
objectives as well as a polarisation filter (for visualisation of
collagen fibres) was used for histological slice assessment.
Evaluation and graduation of findings was performed in a
semiquantitative manner by score point allocation (minimum,
0; maximum, 3) according to common neuropathological
criteria (Table 1). As an exception, the degree of mineral
deposits was multiplied with a second score describing
distribution (focal, 1; multifocal, 2 and diffuse, 3; thus
resulting in minimum, 0 and maximum, 9; see Table 2).
Statistical Analyses
The SPSS statistical software (version 16.0.2; SPSS Inc.,
Chicago) was used for all statistical analyses. The Kolmo-
gorov–Smirmov test was applied to check for normal
distribution of data. As the majority of data was not normally
distributed or ordinally scaled, only non-parametrical tests
Fig. 1 Gross pathology and brain analysis. Four-millimetre-thick
brain slices were taken from brains after fixation, photographed and
used for further analysis (a, occipital view). To calculate ventricular
expansion, total volumes of hemispheres and ventricles were
calculated from the areas of the ipsilateral hemisphere (dark (grey
matter) and middle (white matter) red, without infarct) and ventricle
(light red) as well as contralateral hemisphere (dark (grey matter) and
middle (white matter) blue) and ventricle (light blue, all given in b)
according to Eqs. 1 to 3 in “Materials and Methods”. For histological
investigations of two consecutive slices from three defined regions
(rostral and occipital border of infarction, and level of MCAO)
infarcted areas (black area, with adherent leptomeninx) were discrim-
inated from the bordering reactive zone (200 μm broad, dark grey),
and the remote zone in the ipsilateral hemisphere (c). In the remote
and reactive zone, grey and white matter areas where analysed
separately. Where appropriate, comparison to corresponding areas in
the contralateral hemisphere was also drawn. Scale bar in (a) indicates
1 cm. inf infarct, remote remote zone, contralat. contralateral
hemisphere
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were applied for all analyses. The Wilcoxon test was applied
for pair-wise comparison, whereas the Mann–Whitney U test
was applied for group comparison. A p value <0.05 was
considered statistically significant.
All data are presented as median values±standard error of
the mean (SEM; for non-ordinally scaled data only) or box
plots (white line, median; box edges, 25% and 75% percentile;
whiskers, 95% confidence interval). The asterisk symbol (*)
indicates a statistical difference against total MCAO, whereas
the pound sign (#) indicates difference against partial MCAO.
Single symbols represent p values <0.05, and double symbols
indicate p values <0.01.
Table 1 Criteria for histological evaluation of ovine brain specimen in hematoxylin–eosine and Picrosirius red staining
Degree of alteration (score points)




HE No or very few (0–4)a
fibroblasts












HE None Focally few (<10)a cells Multifocally moderate
(10–50)a numbers of cells
Multifocally many (>50)a











Many (>50)a fibroblasts, pia
mater and collagen fibres






HE None Focally few (<10)a cells Multifocally moderate
(10–50)a numbers of cells
Multifocally many (>50)a
cells or diffuse infiltration
Blood vessel density HE No blood vessels Low density of blood
vessels (<10)a
Moderate density of blood
vessels (10–30)a
High density of blood
vessels (>30)a
Reactive and remote zone, contralateral hemisphere
Cytolytic neuronal
alterationsb
HE None Few (<10%)a Moderate (10–30%)a Many (>30%)a
Spheroidsc HE None Few (1–4)a Moderate (5–20)a Many (>20)a









HE None Focally few (1–4)a cells Multifocally moderate
(5–20)a numbers of cells
Multifocally many (>20)a
cells or diffuse infiltration







a Refers to microscopic field of view at ×10 magnification
b Grey matter only
c Grey and white matter
d Refers to corresponding area in contralateral hemisphere
e Refers to corresponding area in contralateral hemisphere of non-stroked (sham) animals
Degree of alteration (score points)
Aspect No pathology (0) Mild (1) Moderate (2) Severe (3)
Mineral deposits None 1 to 20a 20 to 50a >50a
Distribution (factor for multiplication)
Distribution of deposits focal: x1 multifocal: x2 diffuse: x3
Table 2 Criteria for histological
evaluation of mineral deposits in
the ovine brain specimen using
Kossa staining
a Refers to microscopic field of
view at ×10 magnification
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Results
Animal Welfare, Survival Rates and Transplanted Cell
Numbers
No animal died or had to be euthanized due to poor conditions
(e.g. not qualified for grazing, infectious diseases and fever for
more than 3 days, weight loss >15%, moving inability, stupor)
before completion of the trial. The intended number of 4×106
BM MNC per kilogram of bodyweight was obtained from
each animal that was assigned to the cell transplantation
group.
Part I: Pathohistological Impact of Permanent Partial
and Total MCAO
Gross Pathology and Volumetry
Analysis of MRI data revealed significant differences in
ischaemic lesion size between partial and total MCAO at
day 1 post MCAO (Fig. 2a and b; p<0.01). After brain
removal, data regarding brain weight and circumferences at
day 49 were recorded (Table 3) and brains were photo-
graphed. Lesion surface area was assessed from digital
micrographs. The surface area of the lesion was signifi-
cantly larger in the total MCAO group as compared to the
partial MCAO (21.5±2.2 cm2 versus 7.6±1.0 cm2; Fig. 2c
and d; p<0.01). Similar findings were obtained for the
ventricular expansion (total MCAO 2.9±0.3 versus partial
MCAO 1.6±0.2; Fig. 2e and f; p<0.01). No signs of
cerebral infarction or ventricular expansion were found in
sham-treated subjects. However, a small area of slightly
thickened and opaque leptomeninx (mean extension, 2.6±
1.0 cm2) was observed in the area of surgery in all sham-
operated animals (statistical significance given in brackets
in Fig. 2c; white dotted line indicates affected area in
Fig. 2d).
Histological Findings in the Leptomeninx
Besides the aforementioned thickened and opaque lepto-
menix in the area of craniotomy, no further pathological
Fig. 2 Lesion size assessment and gross pathology. A clear difference
between sham, partial and total MCAO was observed at day 1
following MCAO in T2 TSE MRI scans (a and b). However, no initial
differences in lesion size were observed between total MCAO without
or with BM MNC administration. At day 49, lesion surface
measurement revealed smaller lesion sizes in partial MCAO and BM
MNC subjects as compared to total MCAO (c). Slight leptomeningeal
alterations in the area of trepanation were regularly observed in sham-
treated animals (d, white dotted line), being much smaller than a total
MCAO lesion (c, p<0.01, significance given in brackets). Measure-
ment of ventricular expansion revealed similar findings (e and f).
*/**p<0.05/0.01 versus total MCAO
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findings (in this and all other zones) were observed in
sham-operated subjects. A mild to moderate, chronic and
active (non-infectious) fibrosis with mild infiltration of
mononuclear cells into the leptomeninx was observed in all
animals subjected to MCAO. The assessment of connective
tissue proliferation according to Table 1 showed no differ-
ences between partial MCAO and total MCAO in the
lesioned (Fig. 3a and c–f) and contralateral (Fig. 3b)
hemisphere (p>0.05), but a non-surprising overall increase
of connective tissue in comparison to the contralateral
hemisphere (Fig. 3a and b). Lymphocytic infiltration in the
leptomeninx was comparable between partial and total
MCAO, with a non-significant (p>0.05) enhancement of
lymphocytes in the total MCAO group (Fig. 3g–m).
Histological Findings in the Central Zone
Moderate, but statistically significant differences between
the groups were observed regarding the proliferation of
connective tissue in the central necrotic zone. Connective
tissue proliferation was slightly enhanced in the partial
MCAO as compared to the total MCAO group (p<0.05,
Fig. 4a–c). No differences were observed regarding blood
vessel density (p>0.4, Fig. 4d and e). However, perivas-






Sham (n=3) Mean±SEM 106.0±4.4 22.1±0.8 13.4±1.0
Min–max 99–114 19–24 9–16
Partial MCAO (n=8) Mean±SEM 113.1±5.3 23.4±0.4 16.2±0.6
Min–max 93–139 22–26 13–18
Total MCAO (n=12) Mean±SEM 120.1±4.5 19.8±1.3 11.8±1.3
Min–max 97–140 13–25 8–18
BM MNC (n=12) Mean±SEM 118.0±2.2 23.7±0.5 15.5±0.6
Min–max 104–137 17–25 9–18
Table 3 Brain weights and
largest brain circumferences
Fig. 3 Leptomeningeal findings following MCAO. An active chronic
fibrosis was observed (a and b) in all groups subjected to middle
cerebral artery occlusion with or without BM MNC (c to f, HE
staining). Only a slight increase of connective tissue proliferation was
observed in sham-treated subjects (c). Infiltration with lymphocytes
was observed in all groups (i to m, HE staining, white arrows).
Lymphocytic infiltration was lowest in BM MNC-treated subjects (g,
h) in both hemispheres and compared to partial and total MCAO.
Please note augmentation of fibroblasts (k to m, black arrows) in all
groups subjected to MCAO. Graphs: white line in box plots indicates
the median, whiskers give the 95% confidence interval. */#p<0.05
versus total MCAO/partial MCAO. Scale bar in (f) represents 100 μm
in (c) to (f) and scale bar in (m) indicates 25 μm in (i) to (m),
respectively
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cular lymphocytic infiltration was significantly lower in the
partial MCAO than in the total MCAO group (p<0.01,
Fig. 4f and g). Distribution and amount of mineral deposits
were similar between both groups (p>0.05, Fig. 4h and i).
Representative micrographs from the total MCAO group
for all criteria investigated are given in Fig. 4.
Fig. 4 Histological findings in
the central zone. Proliferation of
connective tissue was slightly
enhanced in the partial MCAO
and BM MNC group (a and b,
Picrosirius red). In polarisation
microscopy, connective tissue
was identified as collagen type I
(yellow, c) and type III (green, c,
Picrosirius red). Blood vessel
density was comparable
between all groups (d) and
numerous blood vessels could
be identified in the infarct core
(c, white arrow; e, black arrows,
Picrosirius red). Lymphocytic
infiltration was less in both, the
partial MCAO and BM MNC
group as compared to total
MCAO (f, p<0.01). Lympho-
cytes (g, white arrows, HE)
were mostly found together with
vast macrophages/foamy fat
cells. No inter-group differences
(but highest medians) were
observed for mineral deposits
(h) in the central zone of BM
MNC-treated subjects. Calcifi-
cations could clearly be identi-
fied by black staining (i, white
arrows, Kossa). All photomi-
crographs presented were taken
from a total MCAO subject.
Graphs: white line in box plots
indicates the median, whiskers
give the 95% confidence inter-
val. Pia pia mater, cz central
zone (former ischaemic core).
*/**p<0.05/0.01 versus total
MCAO. Scale bars in (b) and
(c) represent 100 μm and scale
bars in (e), (g) and (i) represent
50 μm
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Histological Findings in the Reactive Grey and White
Matter Zones
As previously reported [24], the reactive zone bordering the
central lesion was demarked by reactive gliosis, which is
typical after stroke. Almost no cytolytic neurons were
found in the reactive grey matter (cortical) zones of the
partial MCAO group 49 days after MCAO. In contrast,
scattered post-ischaemic (“ghost”) neurons (black asterisks
in Fig. 5a and n) could still be identified in the reactive
cortical areas of total MCAO subjects (p<0.01, quantitative
data not shown). Spheroids (Fig. 5a and b), a typical sign of
axonal degeneration, were found in small numbers in the
cortical reactive zones of both groups. The number of
spheroids observed in the partial and total MCAO groups
were statistically indifferent (p>0.05, Fig. 5b). As expected,
Fig. 5 Histopathological changes in the reactive zone. As expected,
only a few spheroids were identified in grey matter (a, white arrow,
HE, and b). In some cases, few (degenerated) neuronal were also
observed (“ghost cells”; a and n, black asterisks). In white matter, the
number of degenerated axons (c, white arrow, HE) was generally
higher (d). The number of spheroids was smaller in BM MNC group
in both areas, and reduced in partial MCAO subjects in the white
matter. (p<0.05, b and d). Blood vessel (e and g, black arrows,
Picrosirius red) density was indifferent in the grey matter of all groups
(f), but was enhanced in the white matter of partial MCAO and BM
MNC subjects (h). Perivascular infiltrations (i and l, black arrows,
HE) were reduced in grey and white matter of BM MNC animals as
compared to total MCAO (k, p<0.05). In white matter, those
infiltrations were also smaller in partial as compared to total MCAO
(m, p<0.05). Microglial recruitment was indifferent between all
groups in grey matter (n and o, black arrows, p>0.05), but a
significant increase was observed after partial MCAO as compared to
total MCAO (p and q; p<0.05). Microglial response after BM MNC
treatment did not differ from other groups in white matter (q, p>0.05).
However, note the relatively high inter-individual variance in the BM
MNC group (a). All photomicrographs were taken from a total
MCAO subject, graphs: white line in box plots indicates the median;
whiskers give the 95% confidence interval. */#p<0.05 versus total
MCAO/partial MCAO. Scale bars represent 50 μm in (a), (c), (i), (l),
(n) and (p), and 100 μm in (e) and (g), respectively
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more spheroids could be observed in the white matter areas
of the reactive zone of all groups (Fig. 5c). Here, the
number of degenerated axons after total MCAO was
significantly higher than in the partial MCAO group (p<
0.05, Fig. 5d). Blood vessel (Fig. 5e and f) density
(compared to the contralateral hemisphere) was indifferent
in the grey matter reactive zones of partial and total MCAO
groups (p>0.05, Fig. 5f), but was significantly lower in the
white matter reactive zones of total MCAO animals (p<
0.05, Fig. 5g and h). Grey matter perivascular infiltration
with lymphocytes (Fig. 5i and k) was similar in partial and
total MCAO (p>0.05, Fig. 5k). In the white matter,
lymphocyte infiltrations were found to be less frequent in
the partial MCAO than in total MCAO subjects (p<0.05,
Fig. 5l and m). Microglial recruitment was generally
increased following stroke. No statistically significant
differences were observed between partial and total MCAO
in the grey matter areas (p>0.4, Fig. 5n and o). However,
there was a surprising increase of microglial cells in the
white matter areas of partial MCAO subjects (p<0.05,
Fig. 5p and q).
Histological Findings in the Remote Zone
and the Contralateral Hemisphere
In the grey matter of the ipsilateral remote zone and the
contralateral hemisphere, clear signs for hypoxic–ischaemic
neuronal alterations were found among all groups except
for sham animals. However, in the white matter areas, the
number of spheroids was less in the partial MCAO as
compared to the total MCAO group (p<0.05, Fig. 6a).
Blood vessel density was statistically indifferent between
groups and between grey and white matter areas in the
remote zone, although higher median score values were
assessed for partial MCAO in cortical and medullary areas
against total MCAO (p>0.05, Fig. 6b). Interestingly,
perivascular lymphocytic infiltrations were clearly observ-
able in the total MCAO group, but were almost undetect-
able in the partial MCAO group (p<0.05, Fig. 6c; no
quantitative data is shown for Fig. 6a to c). Pathological
findings were always less pronounced in the contralateral
hemisphere.
There was an overall slight to moderate increase of
microglial activation in the remote zones and contralateral
hemispheres of partial and total MCAO subjects, which did
not differ statistically between the groups in the remote
zone (p>0.4, data not shown) and in the contralateral
hemisphere (p>0.05, Fig. 6d).
Part II: Impact of Autologous BM MNC Therapy
on Permanent Total Cortical MCAO
Gross Pathology and Volumetry
Initial lesion size determined at day 1 by MRI showed no
difference between both, treated (BM MNC) and untreated
(control) total MCAO groups (p>0.4, Fig. 2a and b). In
contrast, the lesion extension was significantly larger in
untreated MCAO animals as compared to the BM MNC
group (21.5±2.2 cm2 versus 12.0±3.0 cm2; p<0.01, Fig. 2c
Fig. 6 Findings in the remote
zone and the contralateral hemi-
sphere. Axonal alterations
concerning spheroids were less
prominent in the remote zone
and the contralateral hemisphere
(a, black arrows, HE) as com-
pared to the reactive zone. The
same situation was found for
blood vessels (b, black arrows,
HE) and perivascular infiltra-
tions (c, black arrows). All
representative images were tak-
en from the remote zone of a
total MCAO subject. For the
slight inter-group differences (in
general less alterations in BM
MNC animals), please see main
text. Microglial recruitment after
total MCAO was diminished in
the contralateral hemisphere by
BM MNC treatment (d). Scale
bars represent 100 μm in (a)
and (b) and 50 μm in (c)
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and d) at day 49. Ventricular expansion was also larger in
the total MCAO group (2.9±0.3) as compared to BM
MNC-treated subjects (2.0±0.2; p<0.05, Fig. 2e and f).
Histological Findings in the Leptomeninx
As in other MCAO groups, a non-infectious fibrosis
accompanied by mononuclear cells infiltration into the
leptomeninx was observed in BM MNC-treated subjects. In
the lesioned hemisphere, connective tissue proliferation was
indifferent between BM MNC treatment and untreated
partial or total MCAO animals (Fig. 3a and b–f, p>0.05).
However, lymphocytic infiltration after autologous BM
MNC transplantation as compared to partial and total
MCAO group (p<0.05, Fig. 3g and h). Remarkably, this
was the case for both hemispheres (p<0.05 each).
Histological Findings in the Central Zone
Connective tissue proliferation in the BM MNC group was
similar to the partial MCAO group and slightly enhanced in
comparison to the untreated total MCAO group (p<0.05,
Fig. 4a–c). No differences were observed regarding blood
vessel density (p>0.4, Fig. 4d and e). Lymphocytic
infiltration was also found to be significantly lower in the
BM MNC group as compared to the control MCAO
animals (p<0.01, Fig. 4f and g). Mineral deposits were
indifferent between all groups in grey and white matter (p>
0.05, Fig. 4h and i), but highest median values were
observed for the BM MNC group.
Histological Findings in the Reactive Grey and White
Matter Zones
Seven weeks after MCAO, cytolytic neurons were rarely
found in the reactive grey matter (cortical) zone of BM
MNC-treated subjects. As in the partial MCAO group, only
few post-ischaemic neurons were observed in the reactive
cortical areas of BM MNC animals. These events were less
frequent than in untreated total MCAO subjects (p<0.01).
Numbers of spheroids were significantly lower in grey
matter areas after BM MNC transplantation (p<0.05,
Fig. 5b). In accordance to findings from untreated partial
and total MCAO subjects, more spheroids were found in
the white matter areas of the reactive zone in BM MNC-
treated animals (Fig. 5c). BM MNC treatment reduced the
amount of degenerated axons after total MCAO (p<0.05,
Fig. 5d). While autologous BM MNC treatment did not
alter blood vessel density in the grey matter areas of the
reactive zone (Fig. 5e and f), a significantly higher number
of blood vessels was observed in the white matter of cell-
treated subjects as compared to untreated total MCAO (p>
0.05, Fig. 5g and h). Perivascular infiltration with lympho-
cytes (Fig. 5i and k) was lower in the grey matter of BM
MNC subjects as compared to partial and total MCAO (p<
0.05, Fig. 5k). In the white matter of BM MNC-treated
animals, lymphocyte infiltration was also lower as com-
pared to total MCAO (p<0.05, Fig. 5l and m). The amount
of infiltrating lymphocytes was indifferent from that after
partial MCAO (p<0.05). Results regarding microglial
recruitment showed a high inter-individual variance. Albeit
higher median score values in BM MNC-treated subjects,
there was no difference between total MCAO with or
without BM MNC treatment in the grey matter (p>0.05,
Fig. 5o) and white matter (p>0.05, Fig. 5q) reactive zones.
Histological Findings in the Remote Zone
and the Contralateral Hemisphere
In general, pathological findings in the BM MNC group
were nearly comparable to the situation found in untreated
total MCAO. Notwithstanding this, BM MNC treatment
resulted in an amelioration of axonal degeneration in the
white matter of the remote zone and the contralateral
hemisphere after total MCAO (p<0.05, Fig. 6a). While
blood vessel density was not statistically different after cell
treatment (p>0.05, Fig. 6b), perivascular lymphocytic
infiltrations were absent in BM MNC-treated animals (p<
0.05, Fig. 6c). However, there was a decrease in microglial
recruitment after BM MNC treatment in the contralateral
hemisphere (p<0.05, Fig. 6d) compared to untreated total
MCAO animals.
Discussion
Gross Pathology and Volumetry
In all animals observed, induction of MCAO was associ-
ated with a loss of functional tissue in the effected
hemisphere. As expected, the final lesion extension differed
between partial and total MCAO subjects. Similar findings
were already reported for imaging and behavioural end-
points in that model [24]. Albeit indifferent MRI results
between total MCAO and BM MNC subjects at day 1, the
final lesion extension in BM MNC subjects was closer to
the partial MCAO group, rather than to the total MCAO
group. This indicates that autologous BM MNC adminis-
tration may have the potential to ameliorate the consequen-
ces of ischaemic stroke, which is in accordance with
previous findings. Beneficial impact of intravenous [13]
and intra-arterial [30] administration of BM MNC on lesion
size has been reported. However, relatively short (45 min),
transient occlusions of the middle cerebral artery were
performed in both studies. Though the therapeutic impact
of BM MNC administration could be clearly demonstrated
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in these models, the vessel occlusion time was much shorter
than the average onset-to-needle-time reported for human
stroke patients being successfully subjected to thrombolysis
[31, 32]. Moreover, cell therapies may represent a treatment
option for patients being ineligible for thrombolysis. In
those patients, long lasting (>24 h) or even permanent
vessel occlusion is common. To the best of our knowledge,
the present study for the first time gives evidence that
autologous BM MNC administration may be effective after
permanent MCAO and in the gyrencephalic brain.
Neuronal Loss, Axonal Degeneration and Blood Vessel
Density Following Stroke in Sheep
The loss of cortical neurons and subsequent axonal degener-
ation in the white matter is an important histological correlate
for functional disabilities following stroke. The presence of
cytolytic neuronal alterations was only rarely seen in areas of
the reactive zone bordering the central lesion. This might be
attributed to the permanent occlusion modality resulting in a
sharply demarked ischaemic area, and the prolonged survival
period of 7 weeks in which most of the cytolytic neurons and
cell debris has been removed by phagocytes.
Clear differences between the groups were observed
regarding signs of axonal degeneration. Because cortical
areas predominantly contain neuronal somata, signs for
axonal degeneration are generally rare in grey matter areas
[33]. Nevertheless, there was a statistically significant
reduction of grey matter axonal degeneration after BM
MNC treatment as compared to partial and total MCAO
subjects. In the white matter areas of the reactive and
remote zones, axonal alteration was observed to a smaller
extend in animals subjected to partial MCAO. Less frequent
axonal degeneration in white matter areas in the partial
MCAO group can be explained by a smaller initial lesion
size, subsequently resulting in the degeneration of a smaller
number of fibre tracts. However, a reduced frequency of
axonal degeneration was also found after BM MNC
treatment of total MCAO, being comparable to the situation
after partial MCAO. This was the case in both, the reactive
and the remote zones of the ipsilateral hemisphere. As the
initial size of the ischaemic lesion was comparable between
untreated and BM MNC-treated total MCAO subjects,
these differences are more likely related to processes in the
sub-acute or chronic stage. In fact, BM MNC have been
reported to enhance axonal sprouting and brain plasticity
following stroke [12] in the rat. Protection against ischae-
mic white matter damage by BM MNC was also shown to
be associated with augmented cerebral blood flow in the
affected areas [34], indicating a close relationship between
post-stroke vascularisation, cerebral blood flow and white
matter protection. BM MNC may enhance vascularisation
and blood flow by stimulating the proliferation of endog-
enous endothelial precursor cells [35]. The stimulation of
neural stem and precursor cells in the neuro-vascular niche
[35] may further contribute to enhanced plasticity after
focal cerebral ischaemia. In fact, an increased number of
blood vessels were observed in reactive white areas of the
BM MNC-treated sheep in this study. These areas are
considered to be highly relevant for post-stroke brain
plasticity and functional regeneration [36]. Nevertheless,
more detailed information regarding the in vivo situation,
for example using diffusion tensor MRI technologies and
correlation with neurofunctional outcome will be needed to
verify reported findings in more detail.
Lymphocytic Infiltration as a Major Component
of Stroke Pathophysiology
Lymphocytic infiltrations have been identified as a major
contributor to infarct size and loss of function following
stroke [37]. Consequently, post-stroke inflammatory pro-
cesses, which may last for several days to weeks after the
initial ischaemic event [38], are currently being discussed
as a promising therapeutic target [39]. In our study, the
number and frequency of perivascular lymphocytic infiltra-
tions was found to be increased after a larger stroke (total
MCAO) in all investigated areas including the contralateral
hemisphere. Interestingly, autologous BM MNC adminis-
tration was able to reduce these events after total MCAO to
the level of a smaller initial lesion (partial MCAO).
Lymphocytic infiltrations were virtually absent in the
contralateral hemisphere following BM MNC administra-
tion. As lymphocytic infiltrations are part of a post-stroke
immunoresponse [40], this may emphasize the immuno-
modulatory impact of the cells. Immunomodulatory effects
have been shown for mesenchymal stem cells from bone
marrow [41] as well as for umbilical cord blood MNC [42].
Moreover, neuroprotective and anti-inflammatory mecha-
nisms of BM MNC were recently demonstrated in vitro [8].
In the context of these findings, an immunomodulatory
effect of BM MNC after cerebral ischaemia may also be
assumed for the in vivo situation. However, it still remains
unclear how and to which extend BM MNC can contribute
to the amelioration of post-stroke inflammation. Thus, more
detailed analysis of infiltrating lymphocyte populations, for
example by means of immunohistochemistry and molecular
biology is needed while the kinetic of the process will have
to be elucidated as well. Thereby, the sheep stroke model
may also be used to verify findings that had previously
been obtained in rodent models.
Microglial Recruitment Following Stroke
As expected, there was a clear recruitment of microglial
cells following all MCAO modalities in response to the
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ischaemic lesion. In the ipsilateral hemisphere, there was a
surprising increase of microglial response after partial
MCAO as compared to total MCAO. Comparable median
values were observed after BM MNC treatment, but did not
reach the level of statistical significance, probably due to
high inter-individual variation. Some authors suggest that
an initially decreased, but later increased recruitment of
microglial cells (and thereby stimulation of the release of
microglial-borne mediators like brain-derived neurotrophic
factor) in reactive and remote areas may represent a pro-
regenerative phenomenon [43]. However, as no data
regarding initial microglial activation following partial and
total MCAO (with or without BM MNC treatment) was
obtained in this study, a direct comparison with our data
would be speculative. In the contralateral hemisphere, BM
MNC treatment reduced microglial recruitment as com-
pared to total MCAO, indicating an overall (speculatively
even systemic) anti-inflammatory effect of cell treatment.
This confirms recent results from in vitro studies, monitor-
ing the impact of BM MNC after hypoxic–ischaemic cell
damage [10].
Post-stroke Encrustations/Mineral Deposits
The highest median mineralisation scores in all areas were
observed in the central necrotic area and the reactive zones
of BM MNC-treated subjects, although no statistically
significant difference was observed between the groups. A
comparatively large inter-individual variance could have
contributed to this lack of statistical evidence.
This finding is important as (lack of) calcification and
mineral deposits is an important safety criterion for BM
MNC-based treatment after myocardial infarction. Albeit an
increased rate of such events was not detectable in human
patients in short- [44] and long-term [45] observations,
these findings cannot simply be transferred to the situation
in the brain. Thus, thorough assessment of possibly
enhanced mineralisation, its precise location (intra- versus
extravascular, grey versus white matter) and its relevance
will be important in further translational studies, as
intracerebral mineral deposits represent a risk factor for
ischaemic stroke [46] and thus may be detrimental for
functional recovery following cerebral ischaemia.
Histological Consequences of Stroke in Inter-species
Comparison
Chronic non-infectious fibrosis of the leptomeninx is a
common finding in human specimen [47]. An excessive
inflammatory response following stroke is well-known for
the human situation [48] and includes a reaction of
meningeal cells, which form collagen type I and III during
and after hypoxic–ischaemic conditions [49]. This is
interpreted as part of the reorganisation processes in the
necrotic zone [49]. Interestingly, such processes can only be
observed up to day 15 in the rat [50], but are ongoing for
weeks in human patients [51], as observed in sheep. Thus,
the sheep model can be considered to be closer to the
human situation in this aspect.
The inflammatory situation of the central zone 7 weeks
post MCAO in sheep is characterized by macrophages and
lymphocytes. This is in accordance to findings in humans,
where the presence of these cells is typical for chronic stage
after stroke [51] and can persist up to 53 years. Differences
in the cellular component of post-stroke inflammation were
reported in other large animal models, in which a
dominance of leukocytes with polymorph-shaped nuclei
was observed [52] after stroke induction using a suture
model. In the reactive and remote zones of the infarct,
typical signs of neuronal alterations were observed in
sheep, including axonal degeneration (spheroids) in white
matter. This is also in accordance with findings in human
brain specimen, where signs of hypoxic–ischaemic cell
changes can be observed until day 60 [51] and spheroids
may even persist. In summary, histological investigation
following stroke in sheep revealed typical histological
changes after ischaemic stroke previously reported in
human patients. As the ovine stroke model, in contrast to
rodent models, offers the option to investigate these
processes in a gyrencephalic brain, it may represent a
proper tool for translational stroke research.
Conclusions
The importance of large animal models in translational
stroke research was highlighted by the “Stroke Therapy
Academic Industry Roundtable” (STAIR) and STEPS
expert consortia [18, 19, 23] and may be important to
prevent future failures in clinical translation of cell-based
therapies. In this study, the ovine stroke model was found to
be an adequate model to study the histopathological
alterations and damage following stroke in a gyrencephalic
brain. Consequences of cerebral ischaemia were found to be
similar to those observed after stroke in humans. In
accordance to the already reported impact of lesion size
on behavioural phenotyping [24], a pathohistological
dimension showing diminished histopathological conse-
quences after smaller lesions could be added by this study.
Preclinical data on biodistribution, dose-dependency,
therapeutic time window and safety endpoints are pivotal
for clinical translation of any novel therapeutic concept. In
the field of cell-based therapies, these data are predomi-
nantly available from small animal models, which are
crucial for preclinical research, but may not provide optimal
prediction of the situation in human patients. The sheep
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model may help to bridge this gap in translational stroke
research. In this study, first evidence for potential beneficial
impact of autologous BM MNC therapies in the species
was reported. However, to further assess the impact of BM
MNC therapy on ischaemic stroke in this large animal
model, additional studies will be needed focusing on
imaging and behavioural endpoints, as well as aspects of
astroglial modulations and more detailed description of
microglial response following stroke.
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